3'-propoxybiphenyl-4-amine | 1159499-78-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3'-propoxybiphenyl-4-amine
• 英文别名: 4-(3-propoxyphenyl)aniline
• CAS: 1159499-78-1
• 化学式: C₁₅H₁₇NO
• 分子量: 227.306
• InChiKey: JEIHSDIYUDUEIR-UHFFFAOYSA-N

物化性质

• 沸点：
  367.2±17.0 °C(predicted)
• 密度：
  1.062±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3'-propoxybiphenyl-4-amine 、 N-BOC-2-甲基-L-丝氨酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl (S)-(3-hydroxy-2-methyl-1-oxo-1-((3'-propoxy-[1,1'-biphenyl]-4-yl)amino)propan-2-yl)carbamate
  参考文献：
  名称：

  Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists

  摘要：

  In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modi. cations to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.073
• 作为产物：
  描述：

  4-溴苯胺 、 3-丙氧基苯基硼酸 生成 3'-propoxybiphenyl-4-amine
  参考文献：
  名称：

  NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS

  摘要：

  本发明提供了二氢乳酸酐脱氢酶抑制剂、其制备方法、含有它们的药物组合物以及治疗、预防和/或改善已知抑制二氢乳酸酐脱氢酶显示有益作用的疾病或障碍的方法。

  公开号：

  US20110275603A1

文献信息

• NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110275603A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了脱氢鸟苷酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善疾病或障碍的方法，其中已知抑制脱氢鸟苷酸脱氢酶具有益处效果。
• Immunomodulator and anti-inflammatory compounds
  申请人：Muthuppalaniappan Meyyappan

  公开号：US08686048B2

  公开（公告）日：2014-04-01

  The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了二氢乳酸脱氢酶抑制剂、其制备方法、含有它们的药物组合物以及治疗、预防和/或改善已知抑制二氢乳酸脱氢酶对某些疾病或疾病症状具有有益作用的方法。
• N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases
  申请人：CHIRON CORPORATION

  公开号：EP1258492A1

  公开（公告）日：2002-11-20

  Poly N-substituted Glycines (poly NSGs), wherein the substituents bear purine or pyrimidine bases (R9) every second glycine: In addition, a solid phase method for the synthesis of N-substituted oligomers of more general structures is disclosed.The poly NSGs obtainable by this method can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two "sub-monomers" directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound α-haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using the automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.

  聚 N-取代甘氨酸（poly NSGs），其中每第二个甘氨酸的取代基都带有嘌呤或嘧啶碱（R9）： 此外，还公开了一种用于合成更一般结构的 N-取代低聚物的固相方法。通过这种方法获得的聚 NSG 可以具有多种侧链取代基。每个 N-取代甘氨酸单体由两个 "子单体 "直接在固体支持物上组装而成。每个单体加成循环包括两个步骤：(1) 用包含能被 -NH2 亲核置换的离去基团（如卤乙酸）的酰化剂将与载体结合的仲胺酰化，以及 (2) 通过离去基团的亲核置换引入侧链、(2) 通过亲核置换离去基团，如卤素（作为与树脂结合的 α-卤代乙酰胺）和足量的包含 -NH2 基团的第二亚单体，如伯胺、烷氧基胺、半肼、酰肼、肼基脲或类似物，引入侧链。重复酰化和置换两步循环，即可得到所需的低聚物。利用本方法的自动合成技术可高效合成多种低聚 NSG，这使得这些低聚物在生成和快速筛选各种肽模拟库方面具有吸引力。本发明公开的低聚物，如 N-取代甘氨酸（即多 NSG），提供了一类新的肽类化合物，这类化合物在自然界中并不存在，但可以通过合成获得，而且已被证明具有显著的生物活性和蛋白水解稳定性。
• SYNTHESIS OF N-SUBSTITUTED OLIGOMERS
  申请人：CHIRON CORPORATION

  公开号：EP0671928A1

  公开（公告）日：1995-09-20
• EP0671928A4
  申请人：——

  公开号：EP0671928A4

  公开（公告）日：1997-04-23